Genmab's blood cancer drug fails main goal in late-stage study
Jan 16 (Reuters) - Danish drugmaker Genmab GMAB.CO said on Friday that its experimental drug for a type of blood cancer failed to meet the main goal in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Alan Barona) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Genmab A/S
See all newsBrief: Genmab Q3 Net Sales Of Darzalex At $4.24 Bln
European shares rise as retreating bond yields and oil prices boost risk appetite
Live Markets: Oil prices can rise even with a new MoU
Live Markets: What the AI capex cycle might mean for European growth
Live Markets: Ignore politics and buy the dip in Spain's Bonos